| Literature DB >> 30402173 |
Makoto Samura1, Noriyasu Morikage1, Takahiro Mizoguchi1, Yuriko Takeuchi1, Takashi Nagase1, Takasuke Harada1, Kotaro Suehiro1, Kimikazu Hamano1.
Abstract
Type II endoleak is a common complication that develops after endovascular aneurysm repair. Patients with type II endoleak, which has persisted for 6 months, have a significantly higher rate of aneurysmal sac enlargement, reintervention, and rupture. To date, several studies have examined the effectiveness of preoperative embolization of branch vessels for the prevention of type II endoleak. Particularly, the embolization of the large inferior mesenteric artery (IMA) seems to be a precise, safe, and effective method. IMA is a significant risk factor for type II endoleak. However, there is currently no strong evidence to prove which patients would benefit from preventive IMA embolization. In addition, considering the incidence of type II endoleak and the adverse event rate, routine embolization seems to be unreliable and time-consuming. Moreover, previous reports of preoperative IMA embolization were retrospective. Thus, prospective and randomized studies are necessary so that the usefulness of IMA embolization can be proved and the potential benefits can be assessed. To establish preventive IMA embolization as one of the effective therapeutic strategies to prevent type II endoleak and to maximize its therapeutic effect, we should provide a wide range of therapeutic strategies to suit the state of the patient.Entities:
Keywords: EVAR; IMA embolization; type II endoleak
Year: 2018 PMID: 30402173 PMCID: PMC6200615 DOI: 10.3400/avd.ra.18-00064
Source DB: PubMed Journal: Ann Vasc Dis ISSN: 1881-641X